Reena Philip

4.8k total citations · 1 hit paper
23 papers, 1.1k citations indexed

About

Reena Philip is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Reena Philip has authored 23 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 8 papers in Cancer Research and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Reena Philip's work include Cancer Genomics and Diagnostics (8 papers), Statistical Methods in Clinical Trials (5 papers) and Lung Cancer Treatments and Mutations (5 papers). Reena Philip is often cited by papers focused on Cancer Genomics and Diagnostics (8 papers), Statistical Methods in Clinical Trials (5 papers) and Lung Cancer Treatments and Mutations (5 papers). Reena Philip collaborates with scholars based in United States, France and Australia. Reena Philip's co-authors include Richard Pazdur, Julia A. Beaver, Lisa Rodríguez, Soma Ghosh, Martha Donoghue, Leigh Marcus, Steven J. Lemery, Mengdie Yuan, Lola A. Fashoyin‐Aje and Marc R. Theoret and has published in prestigious journals such as Clinical Cancer Research, Clinical Chemistry and European Journal of Cancer.

In The Last Decade

Reena Philip

23 papers receiving 1.1k citations

Hit Papers

FDA Approval Summary: Pembrolizumab for the Treatment of ... 2021 2026 2022 2024 2021 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors
    2021 330 citations Leigh Marcus, Lola A. Fashoyin‐Aje et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Reena Philip United States 16 583 402 302 293 143 23 1.1k
Ashiq Masood United States 17 574 1.0× 485 1.2× 366 1.2× 308 1.1× 96 0.7× 54 1.2k
Yuka Asano Japan 23 1.0k 1.8× 278 0.7× 289 1.0× 470 1.6× 255 1.8× 111 1.6k
Emmanuel Blot France 19 639 1.1× 543 1.4× 207 0.7× 368 1.3× 154 1.1× 50 1.4k
Elza C. de Bruin United Kingdom 12 567 1.0× 662 1.6× 402 1.3× 628 2.1× 106 0.7× 23 1.4k
Arran Turnbull United Kingdom 23 533 0.9× 602 1.5× 266 0.9× 590 2.0× 104 0.7× 57 1.4k
Takafumi Koyama Japan 19 447 0.8× 293 0.7× 168 0.6× 144 0.5× 136 1.0× 87 871
Howard Fingert United States 23 1.1k 1.8× 765 1.9× 220 0.7× 209 0.7× 100 0.7× 47 1.9k
Chris Womack United Kingdom 16 594 1.0× 595 1.5× 282 0.9× 205 0.7× 87 0.6× 34 1.2k
Geraldine O’Sullivan Coyne United States 17 630 1.1× 361 0.9× 305 1.0× 157 0.5× 185 1.3× 82 1.2k
Jon Holmlund United States 24 537 0.9× 1.1k 2.7× 290 1.0× 184 0.6× 199 1.4× 55 1.7k

Countries citing papers authored by Reena Philip

Since Specialization
Citations

This map shows the geographic impact of Reena Philip's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Reena Philip with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Reena Philip more than expected).

Fields of papers citing papers by Reena Philip

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Reena Philip. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Reena Philip. The network helps show where Reena Philip may publish in the future.

Co-authorship network of co-authors of Reena Philip

This figure shows the co-authorship network connecting the top 25 collaborators of Reena Philip. A scholar is included among the top collaborators of Reena Philip based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Reena Philip. Reena Philip is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lawler, Mark, Olga Kholmanskikh, Nicola Normanno, et al.. (2024). Empowering effective biomarker-driven precision oncology: A call to action. European Journal of Cancer. 209. 114225–114225. 18 indexed citations
2.
Larkins, Erin, Pallavi S. Mishra‐Kalyani, Stephanie Aungst, et al.. (2023). FDA Approval Summary: Amivantamab for the Treatment of Patients with Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. Clinical Cancer Research. 29(17). 3262–3266. 33 indexed citations
3.
Vellanki, Paz J., Soma Ghosh, Anand Pathak, et al.. (2023). Regulatory implications of ctDNA in immuno-oncology for solid tumors. Journal for ImmunoTherapy of Cancer. 11(2). e005344–e005344. 36 indexed citations
4.
Marcus, Leigh, Lola A. Fashoyin‐Aje, Martha Donoghue, et al.. (2021). FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors. Clinical Cancer Research. 27(17). 4685–4689. 330 indexed citations breakdown →
5.
Arora, Shaily, Sanjeeve Balasubramaniam, Hui Zhang, et al.. (2020). FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer. The Oncologist. 26(1). e164–e172. 127 indexed citations
6.
Tsui, Dana W.Y., Gideon M. Blumenthal, Reena Philip, et al.. (2020). Development, Validation, and Regulatory Considerations for a Liquid Biopsy Test. Clinical Chemistry. 66(3). 408–414. 7 indexed citations
7.
Li, You, Janaki Veeraraghavan, & Reena Philip. (2019). Translating Immuno-oncology Biomarkers to Diagnostic Tests: A Regulatory Perspective. Methods in molecular biology. 2055. 701–716. 1 indexed citations
8.
Jen, Emily Y., Aaron J. Schetter, Donna Przepiorka, et al.. (2018). FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease. Clinical Cancer Research. 25(2). 473–477. 98 indexed citations
9.
Odogwu, Lauretta, Luckson Mathieu, Gideon M. Blumenthal, et al.. (2018). FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring BRAF V600E Mutations. The Oncologist. 23(6). 740–745. 166 indexed citations
10.
Odogwu, Lauretta, Luckson Mathieu, Kirsten B. Goldberg, et al.. (2017). FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation. The Oncologist. 23(3). 353–359. 49 indexed citations
11.
Beaver, Julia A., Abraham Tzou, Gideon M. Blumenthal, et al.. (2016). An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted Therapies. Clinical Cancer Research. 23(6). 1368–1372. 26 indexed citations
12.
Roscoe, Donna, Yun‐Fu Hu, & Reena Philip. (2015). Companion diagnostics: a regulatory perspective from the last 5 years of molecular companion diagnostic approvals. Expert Review of Molecular Diagnostics. 15(7). 869–880. 15 indexed citations
13.
Han, Tao, Ching‐Wei Chang, Joshua C. Kwekel, et al.. (2012). Characterization of whole genome amplified (WGA) DNA for use in genotyping assay development. BMC Genomics. 13(1). 217–217. 31 indexed citations
14.
Rodriguez, Henry, Živana Težak, Mehdi Mesri, et al.. (2009). Analytical Validation of Protein-Based Multiplex Assays: A Workshop Report by the NCI-FDA Interagency Oncology Task Force on Molecular Diagnostics. Clinical Chemistry. 56(2). 237–243. 37 indexed citations
15.
Dracheva, Tatiana, Reena Philip, Wenming Xiao, et al.. (2006). Distinguishing lung tumours from normal lung based on a small set of genes. Lung Cancer. 55(2). 157–164. 3 indexed citations
16.
Philip, Reena, et al.. (2005). FDA perspectives on pharmacogenetic testing. Expert Review of Molecular Diagnostics. 5(5). 643–648. 5 indexed citations
17.
18.
Coello, Patricia, Alex de Mendoza, Reena Philip, et al.. (2001). Generation of low phytic acid Arabidopsis seeds expressing an E. coli phytase during embryo development. Seed Science Research. 11(4). 285–291. 10 indexed citations
19.
Philip, Reena, et al.. (1999). A defective seed coat pattern (Net) is correlated with the post-transcriptional abundance of soluble proline-rich cell wall proteins. Plant Molecular Biology. 40(4). 603–613. 20 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ashiq Masood Breakdown of academic impact, for papers by Yuka Asano Breakdown of academic impact, for papers by Emmanuel Blot Breakdown of academic impact, for papers by Elza C. de Bruin Breakdown of academic impact, for papers by Arran Turnbull Breakdown of academic impact, for papers by Takafumi Koyama Breakdown of academic impact, for papers by Howard Fingert Breakdown of academic impact, for papers by Chris Womack Breakdown of academic impact, for papers by Geraldine O’Sullivan Coyne Breakdown of academic impact, for papers by Jon Holmlund
Rankless by CCL
2026